drugset / Trial / NCT02861131
The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications
Phase 4
Completed
200 enrolled
Oregon Health and Science University
Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
Substantial respiratory morbidity has been associated with postoperative residual paralysis, which is fairly common after general anesthesia involving a neuromuscular blocking agent. Common practice in United States is to reverse neuromuscular blockade with neostigmine at the end of surgery. A new drug with evidence of more complete neuromuscular reversal has been developed, sugammadex. The objective of this study is to determine if a strategy of rocuronium neuromuscular reversal with sugammadex will reduce the proportion of subjects with any postoperative pulmonary complication, compared to neostigmine.
Timeline
- Start
- 2017-01-24
- Primary completion
- 2018-04-30
- Completion
- 2018-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Neostigmine | Other / unclassified | 0.07 mg/kg | Intravenous |
| Subject | Sugammadex | Other / unclassified | 2 mg/kg | Intravenous |
Indications
No indication recorded.